DE05075369T1 - Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusähnlichen Teilchen - Google Patents
Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusähnlichen Teilchen Download PDFInfo
- Publication number
- DE05075369T1 DE05075369T1 DE05075369T DE05075369T DE05075369T1 DE 05075369 T1 DE05075369 T1 DE 05075369T1 DE 05075369 T DE05075369 T DE 05075369T DE 05075369 T DE05075369 T DE 05075369T DE 05075369 T1 DE05075369 T1 DE 05075369T1
- Authority
- DE
- Germany
- Prior art keywords
- virus
- particle
- capsomer
- papillomavirus
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002245 particle Substances 0.000 title claims abstract 18
- 108090000565 Capsid Proteins Proteins 0.000 title claims abstract 7
- 102100023321 Ceruloplasmin Human genes 0.000 title claims abstract 7
- 241000701806 Human papillomavirus Species 0.000 title claims abstract 7
- 238000002360 preparation method Methods 0.000 title claims 2
- 241000700605 Viruses Species 0.000 claims abstract 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract 9
- 102000004169 proteins and genes Human genes 0.000 claims abstract 8
- 241001631646 Papillomaviridae Species 0.000 claims abstract 7
- 210000004392 genitalia Anatomy 0.000 claims abstract 6
- 108091026890 Coding region Proteins 0.000 claims abstract 3
- 230000001900 immune effect Effects 0.000 claims abstract 2
- 230000000877 morphologic effect Effects 0.000 claims abstract 2
- 210000002966 serum Anatomy 0.000 claims abstract 2
- 241000701447 unidentified baculovirus Species 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 229960005486 vaccine Drugs 0.000 claims 5
- 241000238631 Hexapoda Species 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 241000341655 Human papillomavirus type 16 Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000010367 cloning Methods 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940031348 multivalent vaccine Drugs 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 238000009877 rendering Methods 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28517 | 1993-03-09 | ||
| US08/028,517 US8062642B1 (en) | 1993-03-09 | 1993-03-09 | Production of papillomavirus capsid protein and virus-like particles |
| US20730994A | 1994-03-07 | 1994-03-07 | |
| US207309 | 1994-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE05075369T1 true DE05075369T1 (de) | 2006-11-16 |
Family
ID=26703787
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE122007000089C Pending DE122007000089I1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen |
| DE69435331T Expired - Lifetime DE69435331D1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichen papillomavirus HBV-11 Kapsidprotein L1 und Virus-ähnliche Partikeln |
| DE05075889T Pending DE05075889T1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem Papilloma-Virus HBV-11-Capsid-Protein L1 und virusähnlichen Teilchen |
| DE122007000090C Pending DE122007000090I1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen |
| DE201112100018 Pending DE122011100018I1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusahnlichen Teilchen. |
| DE69435332T Expired - Lifetime DE69435332D1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem Papillomaviren Hüllprotein und Virus-ähnlichen Teilchen |
| DE69434383T Expired - Lifetime DE69434383T2 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen |
| DE1994634383 Pending DE122007000014I1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem Papillomavirus Hüllprotein und virus-ähnlichen Teilchen |
| DE05075369T Pending DE05075369T1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusähnlichen Teilchen |
Family Applications Before (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE122007000089C Pending DE122007000089I1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen |
| DE69435331T Expired - Lifetime DE69435331D1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichen papillomavirus HBV-11 Kapsidprotein L1 und Virus-ähnliche Partikeln |
| DE05075889T Pending DE05075889T1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem Papilloma-Virus HBV-11-Capsid-Protein L1 und virusähnlichen Teilchen |
| DE122007000090C Pending DE122007000090I1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen |
| DE201112100018 Pending DE122011100018I1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusahnlichen Teilchen. |
| DE69435332T Expired - Lifetime DE69435332D1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem Papillomaviren Hüllprotein und Virus-ähnlichen Teilchen |
| DE69434383T Expired - Lifetime DE69434383T2 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen |
| DE1994634383 Pending DE122007000014I1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem Papillomavirus Hüllprotein und virus-ähnlichen Teilchen |
Country Status (13)
| Country | Link |
|---|---|
| EP (3) | EP0688227B1 (enExample) |
| JP (4) | JPH08507685A (enExample) |
| AT (3) | ATE492289T1 (enExample) |
| AU (3) | AU688759C (enExample) |
| CA (1) | CA2157932C (enExample) |
| DE (9) | DE122007000089I1 (enExample) |
| DK (2) | DK0688227T3 (enExample) |
| ES (3) | ES2242955T4 (enExample) |
| FR (1) | FR11C0022I2 (enExample) |
| LU (3) | LU91313I2 (enExample) |
| NL (3) | NL300265I2 (enExample) |
| PT (2) | PT688227E (enExample) |
| WO (1) | WO1994020137A1 (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0595935T3 (da) | 1991-07-19 | 2003-07-21 | Csl Ltd | Papillomavirusvaccine |
| US5437951A (en) * | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
| US6153201A (en) * | 1993-03-09 | 2000-11-28 | University Of Rochester | Oral immunization with papillomavirus virus-like particles |
| AUPM358894A0 (en) * | 1994-01-31 | 1994-02-24 | Csl Limited | Modified papilloma virus l2 protein and vlps formed therefrom |
| DE4415743C2 (de) | 1994-05-04 | 1996-10-10 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
| US5888516A (en) * | 1994-05-16 | 1999-03-30 | Merck & Co. Inc. | Recombinant papillomavirus vaccines |
| AUPM566794A0 (en) * | 1994-05-17 | 1994-06-09 | University Of Queensland, The | Process and product |
| AU4270196A (en) * | 1994-10-07 | 1996-05-02 | Lutz Gissmann | Papilloma virus-like particles, fusion proteins and process for producing the same |
| AU2003235191B2 (en) * | 1994-10-07 | 2006-09-21 | Loyola University Of Chicago | Papilloma virus-like particles, fusion proteins as well as processes for their production |
| AR004464A1 (es) * | 1994-11-14 | 1998-12-16 | Merck Sharp & Dohme | Un metodo para producir una proteina de capside de papilomavirus |
| US5955087A (en) * | 1995-02-24 | 1999-09-21 | Cantab Pharmaceuticals Research Limited | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation |
| IL117459A (en) * | 1995-03-22 | 2005-11-20 | Merck & Co Inc | Dna encoding human papillomavirus type 18 |
| US5840306A (en) * | 1995-03-22 | 1998-11-24 | Merck & Co., Inc. | DNA encoding human papillomavirus type 18 |
| US5820870A (en) * | 1995-03-22 | 1998-10-13 | Merck & Co., Inc. | Recombinant human papillomavirus type 18 vaccine |
| IL117591A0 (en) * | 1995-03-30 | 1996-07-23 | Merck & Co Inc | Synthetic DNA encoding human papillomavirus type 11 L1 protein |
| US5821087A (en) * | 1995-03-30 | 1998-10-13 | Merck & Co., Inc. | Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA |
| EP0863982B1 (en) * | 1995-11-15 | 2004-01-21 | Merck & Co., Inc. | Synthetic hpv11 virus-like particles |
| DE19543553B4 (de) * | 1995-11-22 | 2009-04-09 | Deutsches Primatenzentrum Gmbh | VP-Antigene des JC-Virus |
| US6908615B1 (en) | 1996-03-18 | 2005-06-21 | Merck & Co., Inc. | DNA encoding human papilloma virus type 18 |
| FR2749323B1 (fr) * | 1996-06-04 | 1998-07-10 | Pasteur Merieux Serums Vacc | Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique |
| EP0956349B1 (en) * | 1996-10-04 | 2003-12-17 | Merck & Co., Inc. (a New Jersey corp.) | Synthetic hpv16 virus-like particles |
| ES2213841T3 (es) * | 1996-12-09 | 2004-09-01 | MERCK & CO., INC. | Particulas sinteticas semejantes al virus hpv16. |
| US6228368B1 (en) * | 1997-10-06 | 2001-05-08 | Loyola University Of Chicago | Papilloma virus capsomere formulations and method of use |
| US7494658B2 (en) | 1998-02-20 | 2009-02-24 | Medigene Ag | Papilloma virus truncated L1 protein and fusion protein constructs |
| US20020039584A1 (en) | 1998-02-20 | 2002-04-04 | Medigene Ag | Papilloma virus capsomere vaccine formulations and methods of use |
| US7182947B2 (en) | 1998-02-20 | 2007-02-27 | Medigene Ag | Papillomavirus truncated L1 protein and fusion protein constructs |
| CA2229955C (en) | 1998-02-20 | 2003-12-09 | Medigene Gmbh | Papilloma virus capsomere vaccine formulations and methods of use |
| US6926897B1 (en) | 1998-03-24 | 2005-08-09 | Medigene Aktiengesellschaft | Medicament for the avoidance or treatment of papillomavirus-specific tumour |
| US6692752B1 (en) | 1999-09-08 | 2004-02-17 | Smithkline Beecham Biologicals S.A. | Methods of treating human females susceptible to HSV infection |
| DE19925199A1 (de) | 1999-06-01 | 2000-12-07 | Medigene Ag | Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie |
| DE19925235A1 (de) | 1999-06-01 | 2000-12-07 | Medigene Ag | Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie |
| CA2422635C (en) * | 2000-09-18 | 2011-11-15 | Medimmune, Inc. | In vitro assay for measuring the immunogenicity of a vaccine |
| GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
| CA2457804C (en) | 2001-08-13 | 2012-10-16 | University Of Rochester | Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles |
| GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| US7534585B2 (en) | 2003-07-21 | 2009-05-19 | Transgene S.A. | Multifunctional cytokines |
| WO2006113209A1 (en) | 2005-04-15 | 2006-10-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
| WO2006065166A1 (en) * | 2005-07-26 | 2006-06-22 | Obschestvo S Ogranichennoi Otvetstvennostyu 'rusgen' | Protein l1 and protein e7 peptide-based composition for treating and preventing a human papillomaviral infection |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| US8778351B2 (en) | 2006-08-30 | 2014-07-15 | University Of Rochester | Combined human papillomavirus VLP/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors |
| SI2468300T1 (en) | 2006-09-26 | 2018-03-30 | Infectios Disease Research Institute | A vaccine composition comprising a synthetic adjuvant |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| HRP20161606T1 (hr) | 2007-03-02 | 2017-01-13 | Glaxosmithkline Biologicals Sa | Novi postupak i pripravci |
| CN101570571B (zh) | 2007-04-29 | 2012-07-11 | 北京万泰生物药业股份有限公司 | 截短的人乳头瘤病毒18型l1蛋白 |
| US9428555B2 (en) | 2007-04-29 | 2016-08-30 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Truncated L1 protein of Human Papillomavirus type 16 |
| DK2154149T3 (da) | 2007-05-29 | 2019-10-14 | Univ Xiamen | En trunkeret l1-protein af human papillomavirus 6 |
| BRPI0810959B1 (pt) | 2007-05-29 | 2021-06-29 | Xiamen Innovax Biotech Co., Ltd. | Proteína l1 do hpv11, polinucleotídeo, vetor, célula, composição, partícula do tipo vírus (vlp) hpv11, método para produzir uma proteína l1 do hpv, vacina para prevenção de condiloma acuminado ou de infecções por hpv e método para produzir uma vacina para prevenção de condiloma acuminado ou infecções por hpv |
| US20110091496A1 (en) * | 2008-01-19 | 2011-04-21 | Graham Barney S | Methods and compositions for the delivery of vaccines to disrupted epithelium |
| US9623098B2 (en) | 2008-05-26 | 2017-04-18 | Cadila Healthcare Limited | Combined measles-human papilloma vaccine |
| GB0815872D0 (en) | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
| GB0820822D0 (en) | 2008-11-13 | 2008-12-24 | Inst Catala D Oncologia | Novel product and processes |
| US20120115207A1 (en) * | 2009-04-03 | 2012-05-10 | Deutsches Krebsforschungszentrum | Enhanced production of papillomavirus-like particles with a modified baculovirus expression system |
| BRPI1011072B1 (pt) | 2009-06-05 | 2021-09-28 | Infectious Disease Research Institute | Composto de gla, composições de vacina e farmacêutica compreendendo dito composto, bem como uso dos mesmos para estimular, induzir ou acentuar uma resposta imune em um indivíduo |
| WO2011026111A1 (en) | 2009-08-31 | 2011-03-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Oral delivery of a vaccine to the large intestine to induce mucosal immunity |
| WO2011127360A1 (en) | 2010-04-08 | 2011-10-13 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | B-cell antigen presenting cell assay |
| WO2012141984A1 (en) | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| WO2013119856A1 (en) | 2012-02-07 | 2013-08-15 | Infectious Disease Research Institute | Improved adjuvant formulations comprising tlr4 agonists and methods of using the same |
| JP2015514696A (ja) | 2012-03-18 | 2015-05-21 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ヒト・パピローマウイルスに対するワクチン接種方法 |
| US9895435B2 (en) | 2012-05-16 | 2018-02-20 | Immune Design Corp. | Vaccines for HSV-2 |
| WO2014066443A1 (en) | 2012-10-23 | 2014-05-01 | Emory University | Gm-csf and il-4 conjugates, compositions, and methods related thereto |
| JP6426706B2 (ja) | 2013-04-18 | 2018-11-21 | イミューン デザイン コーポレイション | がん処置で使用するためのｇｌａ単剤療法 |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| IL310015B1 (en) | 2013-12-31 | 2025-10-01 | Access To Advanced Health Inst | Single vial formulation |
| CN108885212B (zh) | 2016-02-22 | 2022-05-31 | 勃林格殷格翰维特梅迪卡有限公司 | 固定生物分子的方法 |
| EP3458475B1 (en) | 2016-05-16 | 2022-07-27 | Access to Advanced Health Institute | Formulation containing tlr agonist and methods of use |
| US11266602B2 (en) | 2016-05-16 | 2022-03-08 | Infectious Disease Research Institute | PEGylated liposomes and methods of use |
| US11173126B2 (en) | 2016-06-01 | 2021-11-16 | Infectious Disease Research Institute | Nanoalum particles comprising a PAA sizing agent |
| KR20240096685A (ko) | 2017-06-15 | 2024-06-26 | 액세스 투 어드밴스드 헬스 인스티튜트 | 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도 |
| US20200276299A1 (en) | 2017-09-08 | 2020-09-03 | Infectious Disease Research Institute | Liposomal formulations comprising saponin and methods of use |
| US12318436B2 (en) | 2019-05-25 | 2025-06-03 | Access To Advanced Health Institute | Composition and method for spray drying an adjuvant vaccine emulsion |
| WO2022051022A1 (en) | 2020-09-04 | 2022-03-10 | Infectious Disease Research Institute | Co-lyophilized rna and nanostructured lipid carrier |
| CA3210363A1 (en) | 2021-02-11 | 2022-08-18 | Glaxosmithkline Biologicals Sa | Hpv vaccine manufacture |
| IL319329A (en) | 2022-09-09 | 2025-05-01 | Access To Advanced Health Inst | Immunogenic vaccine composition incorporating saponin |
| CN116375816B (zh) * | 2023-01-06 | 2023-09-05 | 北京康乐卫士生物技术股份有限公司 | 一种人乳头瘤病毒56型l1蛋白突变体及减少重组蛋白降解的方法及应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4956288A (en) * | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
| NZ232913A (en) | 1989-03-15 | 1992-08-26 | Gist Brocades Nv | Il-3 produced recombinantly and purified to homogeneity; vectors and pharmaceutical preparations |
| DK0595935T3 (da) * | 1991-07-19 | 2003-07-21 | Csl Ltd | Papillomavirusvaccine |
-
1994
- 1994-03-08 PT PT94912186T patent/PT688227E/pt unknown
- 1994-03-08 JP JP6520236A patent/JPH08507685A/ja not_active Withdrawn
- 1994-03-08 CA CA2157932A patent/CA2157932C/en not_active Expired - Lifetime
- 1994-03-08 WO PCT/US1994/002443 patent/WO1994020137A1/en not_active Ceased
- 1994-03-08 DE DE122007000089C patent/DE122007000089I1/de active Pending
- 1994-03-08 AT AT05075889T patent/ATE492289T1/de not_active IP Right Cessation
- 1994-03-08 AU AU64436/94A patent/AU688759C/en not_active Expired
- 1994-03-08 ES ES94912186T patent/ES2242955T4/es not_active Expired - Lifetime
- 1994-03-08 DK DK94912186T patent/DK0688227T3/da active
- 1994-03-08 DE DE69435331T patent/DE69435331D1/de not_active Expired - Lifetime
- 1994-03-08 DE DE05075889T patent/DE05075889T1/de active Pending
- 1994-03-08 DE DE122007000090C patent/DE122007000090I1/de active Pending
- 1994-03-08 DK DK05075369.8T patent/DK1618888T3/da active
- 1994-03-08 EP EP94912186A patent/EP0688227B1/en not_active Expired - Lifetime
- 1994-03-08 DE DE201112100018 patent/DE122011100018I1/de active Pending
- 1994-03-08 EP EP05075369A patent/EP1618888B1/en not_active Expired - Lifetime
- 1994-03-08 AT AT94912186T patent/ATE296111T1/de active
- 1994-03-08 DE DE69435332T patent/DE69435332D1/de not_active Expired - Lifetime
- 1994-03-08 EP EP05075889A patent/EP1588713B1/en not_active Expired - Lifetime
- 1994-03-08 DE DE69434383T patent/DE69434383T2/de not_active Expired - Lifetime
- 1994-03-08 DE DE1994634383 patent/DE122007000014I1/de active Pending
- 1994-03-08 ES ES05075889T patent/ES2263406T3/es not_active Expired - Lifetime
- 1994-03-08 ES ES05075369T patent/ES2263405T3/es not_active Expired - Lifetime
- 1994-03-08 PT PT05075369T patent/PT1618888E/pt unknown
- 1994-03-08 DE DE05075369T patent/DE05075369T1/de active Pending
- 1994-03-08 AT AT05075369T patent/ATE494005T1/de active
-
2006
- 2006-10-11 JP JP2006277056A patent/JP4486075B2/ja not_active Expired - Lifetime
-
2007
- 2007-02-21 LU LU91313C patent/LU91313I2/fr unknown
- 2007-02-21 NL NL300265C patent/NL300265I2/nl unknown
- 2007-03-07 AU AU2007201005A patent/AU2007201005B2/en not_active Expired
- 2007-03-07 AU AU2007201006A patent/AU2007201006B2/en not_active Expired
- 2007-12-14 NL NL300309C patent/NL300309I2/nl unknown
- 2007-12-14 LU LU91392C patent/LU91392I2/fr unknown
- 2007-12-14 LU LU91391C patent/LU91391I2/fr unknown
- 2007-12-14 NL NL300310C patent/NL300310I1/nl unknown
-
2010
- 2010-02-05 JP JP2010023690A patent/JP5306251B2/ja not_active Expired - Lifetime
- 2010-02-05 JP JP2010023691A patent/JP5386392B2/ja not_active Expired - Lifetime
-
2011
- 2011-07-04 FR FR11C0022C patent/FR11C0022I2/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE05075369T1 (de) | Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusähnlichen Teilchen | |
| LU91317I2 (fr) | Particule similaire au virus HPV6,HPV11,HPV16 et HPV18 | |
| Cann et al. | Self-assembly of human papillomavirus type 16 capsids by expression of the L1 protein in insect cells | |
| NL300323I1 (nl) | Op papillomavirus lijkende deeltjes, fusie-eiwitten alsook werkwijze | |
| RU97110164A (ru) | Очищенные белки вируса папилломы | |
| WO1999061052A3 (en) | Oral immunization with papillomavirus virus-like particles | |
| DE69736779T2 (de) | Zusammensetzungen von rekombinanten papillomavirus vakzinen | |
| DE4435907C2 (de) | Papillomavirusähnliche Partikel und deren Anwendung | |
| EP1183367B1 (de) | Zytotoxisches t-zellepitop des papillomavirus l1-proteins und seine verwendung in diagnostik und therapie | |
| DE29824556U1 (de) | Formulierung mit Papillomavirus-spezifischem Protein |